GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Gross Margin %

Antengene (HKSE:06996) Gross Margin % : 92.43% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Antengene Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Antengene's Gross Profit for the six months ended in Dec. 2023 was HK$-4.76 Mil. Antengene's Revenue for the six months ended in Dec. 2023 was HK$-5.15 Mil. Therefore, Antengene's Gross Margin % for the quarter that ended in Dec. 2023 was 92.43%.


The historical rank and industry rank for Antengene's Gross Margin % or its related term are showing as below:

HKSE:06996' s Gross Margin % Range Over the Past 10 Years
Min: 81.74   Med: 82.43   Max: 84.08
Current: 81.74


During the past 6 years, the highest Gross Margin % of Antengene was 84.08%. The lowest was 81.74%. And the median was 82.43%.

HKSE:06996's Gross Margin % is ranked better than
76% of 750 companies
in the Biotechnology industry
Industry Median: 60.91 vs HKSE:06996: 81.74

Antengene had a gross margin of 92.43% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Antengene was 0.00% per year.


Antengene Gross Margin % Historical Data

The historical data trend for Antengene's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Gross Margin % Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - - 84.08 82.43 81.74

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 84.08 83.87 81.70 82.43 92.43

Competitive Comparison of Antengene's Gross Margin %

For the Biotechnology subindustry, Antengene's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Antengene's Gross Margin % falls into.



Antengene Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Antengene's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=60.2 / 73.617
=(Revenue - Cost of Goods Sold) / Revenue
=(73.617 - 13.446) / 73.617
=81.74 %

Antengene's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-4.8 / -5.153
=(Revenue - Cost of Goods Sold) / Revenue
=(-5.153 - -0.39) / -5.153
=92.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Antengene  (HKSE:06996) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Antengene had a gross margin of 92.43% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Antengene Gross Margin % Related Terms

Thank you for viewing the detailed overview of Antengene's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene (HKSE:06996) Business Description

Traded in Other Exchanges
N/A
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in China and other regions.
Executives
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Mei Jay 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene (HKSE:06996) Headlines

No Headlines